Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected ...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 8.9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

Medically reviewed by Jay N. Yepuri, MD There are various causes of lower abdominal pain, or lower belly pain. The conditions ...